相关实验视频

Updated: May 16, 2025

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

一个向核的鲁 (II) 复合物诱导了在抗西斯普拉丁的瘤细胞中的DNA凝结

Ying Zhou¹, Kai Xiong¹, Tao Feng¹

¹MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510006, P. R. China.

Angewandte Chemie (International ed. in English)

|April 1, 2025

概括

新的复合物通过诱导DNA凝结,防止瘤细胞的修复和促进根除来克服的抗性. 这种新的方法有效地准瘤细胞,提供了一种对抗化疗耐药性的有希望的策略.

科学领域:

化学化学化学
生物化学生物化学
在瘤学瘤学.

背景情况:

传统的化疗,像西斯一样,诱导DNA损伤以杀死瘤细胞.
瘤细胞通过修复药物诱导的DNA损伤而对思丁产生抗性.
西斯的有限疗效源于它无法显著改变DNA构造,从而允许修复酶进入.

研究的目的:

设计新的鲁 (II) 复合物,以克服西斯的耐药性.
通过DNA凝结来研究一种新的瘤细胞根除机制.
开发具有正电荷的复合体,防止DNA修复.

主要方法:

合成四种高价值 (+8) 卢 (RuC3,RuC6,RuC9,RuC12) 复合物,其链长度不同.
对合成复合物的核积累水平的评估.
评估复合物的诱导DNA凝聚和抑制DNA修复酶的能力.
测试复合体对各种瘤细胞系的疗效.

主要成果:

RuC9显示了最高的核积累.
设计的Ru(II) 复合物通过中和DNA骨干的负电荷,诱导显著的DNA凝聚.
DNA凝结有效地阻止了DNA修复酶的结合.
综合体证明有效地根除了多种瘤细胞系,包括耐西斯的细胞系.

结论:

新型Ru(II) 复合物可以通过诱导DNA凝结来克服西斯普拉丁耐药性.
DNA凝结是一种可行的策略,可以防止瘤细胞的DNA修复,并提高化疗的疗效.
这项研究提出了一种通过DNA凝结消除瘤细胞的第一类方法,解决了癌症治疗中的一个关键挑战.

关键词:

这是一种抗瘤药物.对西斯普拉丁的耐药性这就是DNA凝结的过程.药用无机化学药用无机化学鲁丁是一种.

更多相关视频

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

DNA Damage can Stall the Cell Cycle

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...